Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

This publication has 29 references indexed in Scilit:

• Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
  Journal of Antimicrobial Chemotherapy, 2008
• Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals
  Clinical Pharmacology & Therapeutics, 2007
• Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy
  New England Journal of Medicine, 2004
• Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6???8 Weeks After Single-Dose Nevirapine (HIVNET 012)
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
• Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
  The Lancet, 2003
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Replication validity of genetic association studies
  Nature Genetics, 2001
• NEVIRAPINE PHARMACOKINETICS IN PREGNANT WOMEN AND IN THEIR INFANTS AFTER IN UTERO EXPOSURE
  The Pediatric Infectious Disease Journal, 2001
• Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy
  Antimicrobial Agents and Chemotherapy, 2000